Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and commercializing medications for the treatment of skin diseases in the United States. The company's primary product is YCANTH (VP-102), a drug-device combination featuring a topical cantharidin solution with a precision applicator designed for treating molluscum contagiosum and common warts in both adult and pediatric patients. The product has received regulatory approval in Japan and is advancing through phase III clinical trials for additional indications. Verrica also develops VP-315, an oncolytic peptide-based injectable therapy currently in phase II trials for dermatologic oncology conditions, including basal cell carcinoma. The company generates revenue through direct product sales and collaboration agreements with international partners. Headquartered in West Chester, Pennsylvania, Verrica operates with a focused pipeline addressing significant unmet needs in viral and oncologic skin diseases, positioning itself as an innovative player in the specialized dermatology therapeutics market.